Abbott Laboratories Debt to Equity Ratio 2006-2018 | ABT

Current and historical debt to equity ratio values for Abbott Laboratories (ABT) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Abbott Laboratories debt/equity for the three months ending September 30, 2018 was 0.62.
Abbott Laboratories Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2018-09-30 $19.28B $30.90B 0.62
2018-06-30 $19.82B $30.77B 0.64
2018-03-31 $21.15B $31.60B 0.67
2017-12-31 $27.21B $31.10B 0.88
2017-09-30 $23.31B $32.22B 0.72
2017-06-30 $23.81B $31.79B 0.75
2017-03-31 $23.76B $31.55B 0.75
2016-12-31 $20.68B $20.72B 1.00
2016-09-30 $5.98B $20.90B 0.29
2016-06-30 $6.02B $20.80B 0.29
2016-03-31 $5.98B $20.84B 0.29
2015-12-31 $5.87B $21.33B 0.28
2015-09-30 $5.95B $21.22B 0.28
2015-06-30 $5.86B $23.13B 0.25
2015-03-31 $5.93B $21.99B 0.27
2014-12-31 $3.39B $21.64B 0.16
2014-09-30 $3.72B $22.99B 0.16
2014-06-30 $3.40B $23.70B 0.14
2014-03-31 $3.39B $23.49B 0.14
2013-12-31 $3.39B $25.27B 0.13
2013-09-30 $3.40B $23.79B 0.14
2013-06-30 $3.41B $22.43B 0.15
2013-03-31 $3.47B $22.68B 0.15
2012-12-31 $18.09B $26.81B 0.67
2012-09-30 $12.06B $27.10B 0.45
2012-06-30 $12.00B $24.57B 0.49
2012-03-31 $11.86B $25.54B 0.46
2011-12-31 $12.04B $24.53B 0.49
2011-09-30 $13.10B $24.69B 0.53
2011-06-30 $12.63B $26.47B 0.48
2011-03-31 $12.53B $24.72B 0.51
2010-12-31 $12.52B $22.77B 0.55
2010-09-30 $12.91B $21.48B 0.60
2010-06-30 $12.61B $20.00B 0.63
2010-03-31 $10.88B $21.01B 0.52
2009-12-31 $11.27B $23.19B 0.49
2009-09-30 $11.58B $21.38B 0.54
2009-06-30 $11.37B $19.92B 0.57
2009-03-31 $11.68B $17.98B 0.65
2008-12-31 $8.71B $17.52B 0.50
2008-09-30 $9.27B $19.35B 0.48
2008-06-30 $9.58B $18.96B 0.51
2008-03-31 $9.04B $17.98B 0.50
2007-12-31 $9.49B $17.82B 0.53
2007-09-30 $6.48B $15.61B 0.42
2007-06-30 $6.61B $15.33B 0.43
2007-03-31 $6.54B $14.32B 0.46
2006-12-31 $7.01B $14.05B 0.50
2006-09-30 $7.51B $15.63B 0.48
2006-06-30 $8.18B $15.19B 0.54
2006-03-31 $4.15B $14.44B 0.29
2005-12-31 $4.57B $14.42B 0.32
2005-09-30 $3.05B $14.26B 0.21
2005-06-30 $4.72B $14.38B 0.33
2005-03-31 $4.70B $14.18B 0.33
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $122.855B $27.390B
Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.
Stock Name Country Market Cap PE Ratio
Medtronic (MDT) Ireland $126.569B 18.92
Stryker (SYK) United States $63.182B 23.82
Boston Scientific (BSX) United States $49.097B 24.81
Baxter (BAX) United States $34.600B 22.34
Zimmer Biomet Holdings (ZBH) United States $22.421B 14.54
Smith & Nephew SNATS (SNN) United Kingdom $16.589B 0.00
ResMed (RMD) United States $15.674B 29.89
Perrigo (PRGO) Ireland $8.142B 12.36
Bio-Rad Laboratories (BIO) United States $7.677B 49.09
Canopy Growth (CGC) Canada $7.290B 0.00
Hill-Rom Holdings (HRC) United States $6.241B 19.53
Aurora Cannabis (ACB) Canada $5.730B 30.26
Haemonetics (HAE) United States $5.332B 46.90
Insulet (PODD) United States $4.770B 0.00
ICU Medical (ICUI) United States $4.752B 26.48
Hutchison China MediTech (HCM) China $4.204B 0.00
GW Pharmaceuticals (GWPH) United Kingdom $3.765B 0.00
Neogen (NEOG) United States $3.198B 48.43
Agios Pharmaceuticals (AGIO) United States $3.093B 0.00
NuVasive (NUVA) United States $2.886B 26.85
National Vision Holdings (EYE) United States $2.497B 48.30
NxStage Medical (NXTM) United States $1.925B 0.00
Quidel (QDEL) United States $1.917B 24.99
Phibro Animal Health (PAHC) United States $1.327B 18.78
Aphria (APHA) $1.306B 0.00
AtriCure (ATRC) United States $1.204B 0.00
Cardiovascular Systems (CSII) United States $0.991B 1428.00
VAREX IMAGING (VREX) United States $0.918B 18.37
PetIQ (PETQ) United States $0.886B 22.96
Meridian Bioscience (VIVO) United States $0.778B 24.80
Surmodics (SRDX) United States $0.766B 116.65
OraSure Technologies (OSUR) United States $0.752B 42.35
Cerus (CERS) United States $0.726B 0.00
MacroGenics (MGNX) United States $0.693B 0.00
Omeros (OMER) United States $0.687B 0.00
Eagle Pharmaceuticals (EGRX) United States $0.655B 21.00
Lantheus Holdings (LNTH) United States $0.652B 20.17
NanoString Technologies (NSTG) United States $0.527B 0.00
LeMaitre Vascular (LMAT) United States $0.502B 24.65
Owens & Minor (OMI) United States $0.433B 4.90
Quanterix (QTRX) United States $0.433B 0.00
TG Therapeutics (TGTX) United States $0.414B 0.00
Insys Therapeutics (INSY) United States $0.385B 0.00
Evolus (EOLS) United States $0.375B 0.00
VAPOTHERM INC (VAPO) United States $0.350B 0.00
Utah Medical Products (UTMD) United States $0.339B 21.90
Cytosorbents (CTSO) United States $0.295B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.243B 0.00
Surface Oncology (SURF) United States $0.226B 0.00
BioLife Solutions (BLFS) United States $0.207B 279.25
Rockwell Medical (RMTI) United States $0.172B 0.00
Chimerix (CMRX) United States $0.167B 0.00
Fonar (FONR) United States $0.135B 6.77
Imprimis Pharmaceuticals (IMMY) United States $0.115B 0.00
Chembio Diagnostics (CEMI) United States $0.108B 0.00
United-Guardian (UG) United States $0.079B 16.53
Female Health (VERU) United States $0.076B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.070B 0.00
Trinity Biotech (TRIB) Ireland $0.066B 18.27
CAS Medical Systems (CASM) United States $0.055B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.052B 0.00
Neurotrope (NTRP) United States $0.043B 0.00
ImmuCell (ICCC) United States $0.041B 0.00
Capricor Therapeutics (CAPR) United States $0.021B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.019B 0.00
Akers Biosciences Inc (AKER) United States $0.017B 0.00
Senestech (SNES) United States $0.015B 0.00
Cellectar Biosciences (CLRB) United States $0.010B 0.00
Valeritas Holdings (VLRX) United States $0.008B 0.00
NeuroMetrix (NURO) United States $0.006B 0.00